AE Wealth Management LLC Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW)

AE Wealth Management LLC grew its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 14.8% during the second quarter, Holdings Channel reports. The institutional investor owned 4,618 shares of the medical research company’s stock after purchasing an additional 594 shares during the quarter. AE Wealth Management LLC’s holdings in Edwards Lifesciences were worth $427,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its stake in Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after buying an additional 2,390,137 shares in the last quarter. CIBC Private Wealth Group LLC grew its position in shares of Edwards Lifesciences by 197.0% in the fourth quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock valued at $262,815,000 after purchasing an additional 2,286,119 shares in the last quarter. Sands Capital Management LLC raised its stake in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock valued at $465,407,000 after purchasing an additional 1,567,526 shares during the period. CCLA Investment Management lifted its holdings in Edwards Lifesciences by 100,739.7% during the 1st quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock worth $134,092,000 after purchasing an additional 1,405,319 shares in the last quarter. Finally, Swedbank AB bought a new position in Edwards Lifesciences in the 1st quarter worth about $124,511,000. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,133,916.72. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,250 shares of company stock worth $1,218,138. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.6 %

Shares of Edwards Lifesciences stock opened at $65.77 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The stock has a market capitalization of $39.63 billion, a PE ratio of 28.35, a P/E/G ratio of 2.80 and a beta of 1.13. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company’s fifty day simple moving average is $68.58 and its 200-day simple moving average is $82.31.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the previous year, the company posted $0.66 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 6.7% on a year-over-year basis. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on EW shares. Bank of America downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $105.00 to $75.00 in a report on Thursday, July 25th. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. TD Cowen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Finally, Truist Financial decreased their target price on Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Sixteen investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $79.82.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.